Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King Needs Second Trial In Order To Get Pediatric Extension for Altace

This article was originally published in The Pink Sheet Daily

Executive Summary

The company has until October 2008 to complete another study after initial FDA rejection.

You may also be interested in...



Altace Follow-On Could Clear FDA By Year-End

New formulation from Arrow would allow King to extend the life of its ramipril brand.

King Signs Generic Altace Distribution Agreement With Cobalt

Patent infringement litigation between the two companies is ongoing.

GAO Urges Congress To Place EPO, Other Dialysis Services In Bundled Rates

The Government Accountability Office recommends that Congress establish a bundled payment system for end-stage renal disease services - including Amgen's Epogen (epoetin) - under Medicare Part B "as soon as possible.

Topics

UsernamePublicRestriction

Register

PS063903

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel